HOME > NATION > Article

Text Size

small

medium

large


Kishida Visits Site for Oral COVID-19 Drug Clinical Trial

Kishida Visits Site for Oral COVID-19 Drug Clinical Trial

   Yokohama, Oct. 10 (Jiji Press)--Japanese Prime Minister Fumio Kishida on Sunday visited a facility where Shionogi & Co. <4507> is conducting a clinical trial for its orally taken novel coronavirus drug.
   At the accommodation facility designated as a place to host COVID-19 patients in Yokohama, Kanagawa Prefecture, south of Tokyo, Kishida received explanations from Shionogi President Isao Teshirogi about how the new drug is being administered and observed the way a patient's health is being monitored.
   "This is an effort that will be key to overcoming the coronavirus crisis," the prime minister told reporters after the visit, expressing hope that the oral COVID-19 drug will be put into practical use at an early date.
   Touching on the fact that the number of coronavirus patients staying at home across Japan exceeded 130,000 in September, Kishida said: "We must prevent something like this from happening again. For that purpose, an oral drug would be crucial."

To read a full story, please click here to find out how to subscribe.

NATION

Aomori Tourism Information

HEADLINES

POLITICS
1,051 Candidates Registered for Oct. 31 Election of Japan's 465-Seat Lower House
ECONOMY
Suntory Develops Vending Machine to Promote Chatting among Workers
SPORTS
Japanese Baseball: Retiring Saitama Seibu Pitcher Matsuzaka Start for Last Time
OTHER
Fewer People Back Prioritizing Coronavirus Steps over Economy: 6-Nation Poll

AFP-JIJI PRESS NEWS JOURNAL


Photos